May 11, 2023

Catalyst CEO and Founder Nancy Bradish Myers provided her perspective on FDA hybrid/telework policies and the impact of any potential changes in the future. With over 2,000 vacancies at the agency, a hiring push is under way, particularly given new funding provided under PDUFA VII for hiring in certain areas. The article highlights the positive impact the hybrid work environment has had on FDA morale in recent years, but that there is a House-led effort to require federal workers to return to in-person, pre-COVID work arrangements (and the Administration would like to see employees work in person more often).  While the article cites a 2021 survey of FDA’s Centers showing that over a quarter of those staff would consider leaving the agency if they were permitted to work from home more often elsewhere, it also noted Ms. Myers’ view that “returning to the office may help the careers of young scientists who need mentorship that is difficult to provide over Zoom.”

Thank you! Your submission has been received!
Download file
Oops! Something went wrong while submitting the form.

Recent News

NEW WHITE PAPER: Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (Preprint)

Multistakeholder collaboration, led by Catalyst Healthcare Consulting, to Recommend Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (preprint).

Read more

Catalyst, in collaboration with the Emily Whitehead Foundation, publishes Amplifying the Voice of CAR T-Cell Therapy Patients and Caregivers

Understanding the patient experience with CAR-T long-term follow-up (LTFU) is essential for building a sustainable model. Catalyst...

Read more

Recent blogs

Nancy Myers Speaks on Better Leveraging Existing Knowledge During OTP Public Listening Meeting

Catalyst CEO, Nancy Myers, had the opportunity to address CBER leadership during OTP’s September 18th public listening meeting titled “Leveraging Knowledge for Facilitating the Development and Review of Cell and Gene Therapies.” Though a PDUFA VII commitment and a required action, meetings like this one provide a critical space for industry and the Agency to share ideas and deliver better outcomes for patients.

Read more

Plan for Consolidating FDA’s Adverse Event Reporting Systems: Good Idea but Easier Said than Done

Read more

NEW WHITE PAPER: Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (Preprint)

Multistakeholder collaboration, led by Catalyst Healthcare Consulting, to Recommend Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (preprint).

Read more